Peginterferon alfa-2b
| Clinical data | |
|---|---|
| Trade names | PegIntron, Sylatron, ViraferonPeg, others |
| AHFS/Drugs.com | Professional Drug Facts |
| MedlinePlus | a605030 |
| Routes of administration | Subcutaneous injection |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Elimination half-life | 22–60 hrs |
| Identifiers | |
| |
| CAS Number | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| ChEMBL | |
| ECHA InfoCard | 100.208.164 |
| Chemical and physical data | |
| Formula | C860H1353N229O255S9 |
| Molar mass | 19269.17 g·mol−1 |
| (what is this?) (verify) | |
Pegylated interferon alfa-2b is a drug used to treat melanoma, as an adjuvant therapy to surgery. Also used to treat hepatitis C (typically, in combination with ribavirin), it is no longer recommended due to poor efficacy and adverse side-effects. Subcutaneous injection is the preferred delivery method.
Belonging to the alpha interferon family of medications, the molecule is PEGylated to prevent breakdown. Approval for medical use in the United States was granted in 2001. It is on the World Health Organization's List of Essential Medicines as a therapy for chronic hepatitis C.